Expression of SOX9 and P63: A Study of 200 Cases to Determine Their Role in Human Gastric Cancer
Camtu D. Truong,Feng Wei,Wěi Li,Sadir Alrawi,Thaer Khoury,James C. Yao,Keping Xie,Dongfeng Tan
IF: 11.2
2008-01-01
Cancer Research
Abstract:2197 Background: SOX9, a member of highly mobility group box transcription factor family, has recently been implicated in the development, homeostasis and disease of the gastrointestinal tracts. P63, an isolated p53 homologue, has been used as a marker for metaplastic carcinoma. Expression of SOX9 and p63 have been associated with myoepithelial differentiation of cells. However, the role of SOX2 and p63 in gastric cancer has not been evaluated. The aims of this study were to examine the expression pattern of SOX9 and p63 in human gastric cancer, and to assess their diagnostic value in gastric cancer. Design: The study consisted of200 consecutive patients with gastric cancer who had received no preoperative treatment. Immunohistochemical analysis was performed using monoclonal antibodies against SOX9 and p63. Unequivocal nuclear staining was recorded as positive, ranging from 1+ to 3+ and depending on the number of positive cells and staining intensity. Normal gastric tissue was used as control. The expression of SOX9 and p63 was analyzed, along with clinicopathologic parameters which included age, sex, as well as location, size, histology, and pathologic stage of the tumor. Results: SOX9 was readily seen in antral-type glands (1+), and for tumor cases, 66 were negative, and 85, 34, and 15 were 1+, 2+, and 3+ positive for SOX9, respectively. SOX9 tended to be more frequently expressed in well to moderately differentiated carcinoma than in poorly differentiated cancer (p = 0.06). For p63, 191 cases were negative, and 5, 1, and 3 cases were 1+, 2+, and 3+ positive, respectively. Among the nine p63-positive cases, all were sarcomatoid carcinoma. Specifically, p63 was expressed only in the sarcomatoid component of sarcomatoid carcinoma, but not in the adenocarcinoma component (p